Rafferty Asset Management’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-5,432
Closed -$139K 1174
2024
Q1
$139K Sell
5,432
-65,862
-92% -$1.69M ﹤0.01% 1070
2023
Q4
$1.97M Sell
71,294
-3,277
-4% -$200K 0.01% 677
2023
Q3
$4.53M Sell
74,571
-17,302
-19% -$1.22M 0.03% 403
2023
Q2
$6.05M Buy
91,873
+6,451
+8% +$472K 0.03% 373
2023
Q1
$5.43M Buy
85,422
+27,264
+47% +$3.11M 0.04% 367
2022
Q4
$8.05M Buy
58,158
+9,629
+20% +$1.36M 0.07% 261
2022
Q3
$6.14M Buy
48,529
+35,416
+270% +$4.01M 0.07% 280
2022
Q2
$1.09M Sell
13,113
-35,843
-73% -$2.78M 0.01% 620
2022
Q1
$4.75M Buy
48,956
+19,530
+66% +$2.58M 0.03% 402
2021
Q4
$5.88M Buy
29,426
+15,972
+119% +$3.77M 0.03% 313
2021
Q3
$3.33M Buy
13,454
+7,237
+116% +$2.07M 0.02% 420
2021
Q2
$2.58M Sell
6,217
-9,780
-61% -$3.87M 0.02% 584
2021
Q1
$6.25M Buy
15,997
+12,927
+421% +$6.37M 0.04% 244
2020
Q4
$1.72M Sell
3,070
-83
-3% -$52.6K 0.02% 431
2020
Q3
$2.2M Buy
3,153
+1,999
+173% +$1.56M 0.03% 385
2020
Q2
$912K Buy
1,154
+757
+191% +$571K 0.01% 571
2020
Q1
$236K Sell
397
-2,978
-88% -$2.9M 0.01% 486
2019
Q4
$3.84M Sell
3,375
-1,399
-29% -$1.52M 0.06% 175
2019
Q3
$5.68M Buy
4,774
+1,530
+47% +$2.34M 0.09% 140
2019
Q2
$5.34M Buy
3,244
+486
+18% +$841K 0.09% 148
2019
Q1
$5.62M Buy
+2,758
New +$4.86M 0.09% 119

Other funds holding BLUE

Rafferty Asset Management's BLUE Position: Q2 2024 in Review

Rafferty Asset Management sold out of bluebird bio (BLUE) in Q2 2024, closing a stake of 5,432 shares — an estimated $139K sold.

Rafferty Asset Management first reported a position in BLUE in Q1 2019 and held it in 21 quarters. The position peaked at $8.05M in Q4 2022. 150 funds tracked by Wall St. Rank hold BLUE as of Q2 2024.

  • Rafferty Asset Management reported no remaining bluebird bio position as of Q2 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 5,432 bluebird bio shares in Q2 2024, an estimated $139K.
  • Rafferty Asset Management first reported a position in bluebird bio in Q1 2019 and held it in 21 quarters.
  • Rafferty Asset Management's bluebird bio position peaked at $8.05M in Q4 2022.
  • 150 funds tracked by Wall St. Rank held bluebird bio as of Q2 2024.

Based on Rafferty Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.